Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hyperhidrosis Treatment Market

Hyperhidrosis Treatment Market Analysis

  • Report ID: GMI9862
  • Published Date: Jun 2024
  • Report Format: PDF

Hyperhidrosis Treatment Market Analysis

Based on type, the market is classified into axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, and other types. The axillary hyperhidrosis segment dominated the global hyperhidrosis market with 44.8% of market share in 2023.

 

  • Axillary hyperhidrosis, or excessive underarm sweating, is one of the most common forms of hyperhidrosis, affecting a significant portion of individuals suffering from this condition.

     

  • The high prevalence of axillary hyperhidrosis compared to other forms like palmar (hands) or plantar (feet) hyperhidrosis means there is a larger target population for treatments. This contributes to the larger market share for axillary hyperhidrosis treatments.

     

  • Further, the axillary hyperhidrosis segment benefits from a wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers. These include topical antiperspirants, botulinum toxin injections (such as Botox), and microwave thermolysis (such as MiraDry). thereby driving the growth of axillary hyperhidrosis segment.

     

Based on treatment, the hyperhidrosis treatment market is segmented into topical treatment, oral medications, botulinum toxin injections, iontophoresis, and surgical treatment. The topical treatment segment accounted for majority of market share and was valued at USD 255.9 million in 2023.

 

  • Topical treatments, such as antiperspirants, are readily available over the counter, making them a first-line treatment option for many individuals. Their ease of use allows patients to apply these treatments directly to the affected areas without needing medical supervision, appealing to a broad audience.

     

  • Additionally, topical treatments are generally more affordable than other options like botulinum toxin injections or surgical procedures, making them an attractive and accessible choice for a wide range of patients.

     

  • Thus, owing to the advantages such as widespread accessibility, convenience, and cost-effectiveness, the topical treatment segment is anticipated to witness lucrative growth over coming years.

 

Hyperhidrosis Treatment Market, By Age (2023)

Based on age, the hyperhidrosis treatment market is divided into below 50 years and above 50 years. The below 50 years segment held highest market share and is anticipated to grow at 5.2% of CAGR over the analysis period.

 

  • The below 50 years age segment holds the highest market share in the market primarily due to the higher prevalence of the condition in this demographic.

     

  • Hyperhidrosis often begins in adolescence or early adulthood, leading to a larger affected population among younger individuals.

     

  • Further, this age group is more aware about available treatment options and willing to try new therapies to manage their symptoms effectively. These factors collectively drive the growth of this segment in global market.

     

Based on end-user, the hyperhidrosis treatment market is categorized into hospitals, ambulatory surgical centers, dermatology clinics, and other end-users. The hospitals segment accounted for significant market share in 2023 and is expected to reach USD 562 million by 2032.

 

  • Hospitals provide access to advanced treatments and technologies necessary for managing hyperhidrosis effectively. Procedures like botulinum toxin injections, microwave thermolysis, laser therapies, and surgical interventions are routinely performed in hospital settings, attracting patients seeking comprehensive and specialized care.

     

  • Moreover, hospitals employ a wide range of healthcare professionals, including dermatologists, neurologists, and surgeons, who possess the expertise needed to diagnose and treat hyperhidrosis accurately. This expertise instills confidence in patients, leading to higher utilization of hospital-based treatments.

 

North America Hyperhidrosis Treatment Market, 2021 – 2032 (USD Million)

North America hyperhidrosis treatment market was valued at USD 280.7 million in 2023 and is anticipated to grow with CAGR of 5% to reach USD 437.2 million by 2032.

 

  • The region boasts advanced healthcare infrastructure, offering patients access to a wide array of treatment options facilitated by modern facilities and skilled healthcare professionals.

     

  • Additionally, technological advancements and ongoing research initiatives further enhance the region's prominence by continually improving treatment modalities.

     

  • These factors drive the growth of North America market.

     

The U.S. hyperhidrosis treatment market is predicted to witness growth at 4.9% of CAGR over the coming years.

 

  • The high prevalence of hyperhidrosis among the American population, coupled with increased awareness about the condition, has spurred demand for effective treatment options.

     

  • For instance, as per an article published in the Journal of Dermatology, the prevalence of hyperhidrosis in the U.S. population was 2.8% to 4.8%. Thus, the high prevalence of hyperhidrosis, coupled with growing awareness of the condition and available treatment options, drives demand for hyperhidrosis treatments in the country.

     

Germany hyperhidrosis treatment market accounted for a significant position in global market.

 

  • Germany is a leader in technological advancements and medical research, particularly in the field of dermatology and aesthetic medicine.

     

  • The country's pharmaceutical companies, medical device manufacturers, and research institutions are at the forefront of developing innovative therapies, conducting clinical trials, and advancing treatment modalities for hyperhidrosis.

     

  • These advancements lead to the introduction of new and improved treatment options, enhancing Germany's attractiveness as a hub for hyperhidrosis treatment innovation and driving its position in global market.

     

China hyperhidrosis treatment market is anticipated to grow significantly during the forecast period.

 

  • According to National Institutes of Health, the prevalence of primary hyperhidrosis in China was estimated to around 14.5%. This prevalence indicates a substantial portion of the population experiencing excessive sweating, creating a large potential market for hyperhidrosis treatments.

     

  • As more individuals seek relief from the symptoms of hyperhidrosis, there is a corresponding increase in demand for effective treatment options, driving growth in the market.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global hyperhidrosis treatment industry was valued at USD 671.6 million in 2023 and is anticipated to register 5.3% CAGR between 2024 and 2032 due to the increasing prevalence of hyperhidrosis and growing awareness and diagnosis rates.

The axillary segment in the market held 44.8% revenue share in 2023 due to high prevalence of axillary hyperhidrosis and wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers.

North America hyperhidrosis treatment market size is expected to record 5% CAGR between 2024 and 2032 due to the presence of advanced healthcare infrastructure, technological advancements and ongoing research initiatives.

AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel, Inc., Eirion Therapeutics, Inc, Eli Lilly and Company, Intas Pharmaceuticals Ltd and Kaken Pharmaceutical Co., Ltd., among others.

Hyperhidrosis Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 13
  • Tables & Figures: 331
  • Countries covered: 22
  • Pages: 189
 Download Free Sample